Senseonics Holdings has demonstrated accelerating revenue growth, with a 117.8% YoY increase in Q2 2026, and improved gross margins to 59.1%, suggesting strong market adoption.
Price trend, volume and key moving averages
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.63-2.8% vs -$0.61 | $15M+8.6% vs $13M |
Q2 2026 May 7, 2026 | -$0.71-3.6% vs -$0.69 | $12M+19.1% vs $10M |
Q2 2026 Mar 2, 2026 | -$0.46-7.0% vs -$0.43 | $14M+0.4% vs $14M |
Q4 2025 Nov 5, 2025 | -$0.43-30.3% vs -$0.33 | $8M+1.3% vs $8M |
First clinical evaluation of investigational, transmitter-free one-year CGM marks an important milestone on Senseonics' innovation roadmap, with potential launch in 2028
GERMANTOWN, Md., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the following investor conferences in November: Stifel 2026 Healthcare Conference – November 10-12, 2026 (New York, NY) Management will participate in a fireside chat at 3:20 pm ET and host one-on-one meetings with investors on Tuesday, November 10th.
GERMANTOWN, Md., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2026 financial results after market close on Monday, November 9, 2026.
Senseonics is rated Hold due to positive sales growth, margin improvement, and product differentiation, but with significant adoption and funding risks. SENS's Eversense 365 offers unique implantable CGM technology, but recurring revenue depends on repeat implantations and overcoming barriers like prescriber adoption and insurance approvals. Q2 2026 saw 117.8% sales growth and gross margin improvement to 59.1%, but high SG&A expenses, ongoing dilution, and negative free cash flow persist.
Benchmark SENS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Senseonics Holdings, Inc. (SENS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.59 | $359.01M | -4.54 | 56.89% | -225.34% | -165.83% | — | |
| $79.41 | $30.64B | 30.73 | 15.6% | 19.41% | 36.5% | — | |
| $109.93 | $191.48B | 40.64 | 5.67% | 9.75% | 9% | 2.14% | |
| $146.51 | $10.15B | 23.74 | 30.73% | 13.45% | 29.48% | — | |
| $16.91 | $1.16B | -23.92 | 7.93% | -4.58% | -35.61% | — | |
| $71.05 | $9.58B | 17.33 | 16.65% | 17.76% | 11.82% | — |
Senseonics Holdings, Inc. (SENS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Senseonics Holdings, Inc. (SENS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 8, 2026·SEC
May 20, 2026·SEC
Get notified when SENS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Senseonics Holdings, Inc. (SENS) stock FAQ — growth, dividends, profitability & financials explained
Senseonics Holdings, Inc. (SENS) reported $48.5M in revenue over the trailing twelve months. Revenue was $35.3M in fiscal year 2025. That is 207294% more than the $0.0M of fiscal year 2013.
Senseonics Holdings, Inc. (SENS) grew revenue by 90.6% over the trailing twelve months, compared with the twelve months before.
No. Senseonics Holdings, Inc. (SENS) reported a net loss of $109.4M over the trailing twelve months.
Senseonics Holdings, Inc. (SENS) had a return on equity (ROE) of -165.8% over the trailing twelve months. A negative ROE means the company lost money over the period.
Senseonics Holdings, Inc. (SENS) had negative free cash flow of $96.8M over the trailing twelve months.
